Gene · 1048
Papers3,868
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 3,868
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Serum tRF5-23-GlyTCC-2 Functions as a Tumor Suppressor and Novel Biomarker for Colorectal Cancer. | Cancer Manag Res | 2025 | 41180354 | PubTator, text mining | PubMed |
| Serum Nectin-4 as a Potential Prognostic Biomarker for Extramammary Paget Disease. | Exp Dermatol | 2025 | 41123286 | PubTator, text mining | PubMed |
| Plasma Proteome Profiling Identifies Biomarkers and Potential Drug Targets for Non-Small Cell Lung Cancer. | Int J Med Sci | 2025 | 41049426 | PubTator, text mining | PubMed |
| Identification of key molecules in micropapillary progression of lung adenocarcinoma: A comprehensive gene expression analysis study using the spatial gene expression solution methodology. | Oncol Lett | 2025 | 41040912 | PubTator, text mining | PubMed |
Evaluation of the Safety, Pharmacokinetics, and Antitumor Activity of Tusamitamab Ravtansine in Patients With Nonsquamous NSCLC With High or Moderate Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5. | JTO Clin Res Rep | 2025 | 41031047 | PubTator, text mining | PubMed |
| Silva pattern-guided proteomics reveals coordinated tumor-stroma remodeling in cervical adenocarcinoma. | Gynecol Oncol | 2025 | 41014943 | PubTator, text mining | PubMed |
| A circulating microRNA panel enhances the diagnosis of cholangiocarcinoma. | PLoS One | 2025 | 40996984 | PubTator, text mining | PubMed |
| Advances in Adoptive Cell Therapies in Cancer: From Mechanistic Breakthroughs to Clinical Frontiers and Overcoming Barriers. | Med Sci (Basel) | 2025 | 40981188 | PubTator, text mining | PubMed |
| Spatiotemporal multi-omics analysis uncovers NAD-dependent immunosuppressive niche triggering early gastric cancer. | Signal Transduct Target Ther | 2025 | 40976783 | PubTator, text mining | PubMed |
| The Therapeutic Potential of Photoimmunotherapy as a Safe, Effective and Non-Toxic Treatment Option for Superficial Triple Negative Breast Cancer. | Cancer Med | 2025 | 40970572 | PubTator, text mining | PubMed |
| ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell-Dependent Tumor Immunity and Synergizes with PD-1 Blockade. | Cancer Immunol Res | 2025 | 40928366 | PubTator, text mining | PubMed |
| Molecular Characteristics, Heterogeneity, Plasticity, and Cell of Origin of Neuroendocrine Bladder Cancer. | Cancer Heterog Plast | 2025 | 40893664 | PubTator, text mining | PubMed |
| An anti-CEA affibody showing high-definition staining in human pancreatic cancer tissue sections and selective tumor targeting in vivo. | Transl Oncol | 2025 | 40882560 | PubTator, text mining | PubMed |
| Targeting CEACAM5: Biomarker Characterization and Fluorescent Probe Labeling for Image-Guided Gastric Cancer Surgery. | Biomedicines | 2025 | 40868067 | PubTator, text mining | PubMed |
| Mechanistic Insights and Clinical Implications of ELK1 in Solid Tumors: A Narrative Review. | Cells | 2025 | 40862737 | PubTator, text mining | PubMed |
| A contractility-competent immortalized human sweat gland myoepithelial line with dual epithelial-mesenchymal characteristics. | Burns | 2025 | 40858094 | PubTator, text mining | PubMed |
| Prognostic and Monitoring Utility of Serum CEA in Lung Adenocarcinoma: Differential Roles in EGFR-TKI and Chemotherapy Treatments. | Cancer Med | 2025 | 40856433 | PubTator, text mining | PubMed |
| Advancements and challenges in CAR-T cell therapy for solid tumors: A comprehensive review of antigen targets, strategies, and future directions. | Cancer Cell Int | 2025 | 40849468 | PubTator, text mining | PubMed |
| Machine learning-driven multi-targeted drug discovery in colon cancer using biomarker signatures. | NPJ Precis Oncol | 2025 | 40847045 | PubTator, text mining | PubMed |
| Surgical management and adverse factors for recurrence and long-term survival in adenoid cystic carcinoma patients with intracranial extension: A retrospective cohort study. | Medicine (Baltimore) | 2025 | 40826709 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/1048/papers?page=6